Foghorn Therapeutics Inc (FHTX) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.59x

Foghorn Therapeutics Inc (FHTX) has a Cash Flow Reinvestment Rate of 0.59x as of March 2022, reinvesting $159.41 Million (capex $247.00K plus investments $-159.16 Million) from operating cash flow of $271.53 Million. Explore FHTX capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.59x
(Capex + Investments) / Operating CF

Total Reinvested

$159.41 Million
Capex + Investments

Operating Cash Flow

$271.53 Million
USD

Capital Expenditures

$247.00K
USD

Foghorn Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Foghorn Therapeutics Inc across 1 annual periods. Also explore how large is Foghorn Therapeutics Inc's balance sheet for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Foghorn Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Foghorn Therapeutics Inc. For live market cap and broader valuation context, see Foghorn Therapeutics Inc market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 1.26x $244.32 Million $193.61 Million $1.21 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow